MCRB - Seres Therapeutics Inc Stock Price, Fair Value and News

$17.36+0.66 (+3.95%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MCRB Price Action

Last 7 days

2.9%

Last 30 days

13.9%

Last 90 days

-7.7%

Trailing 12 Months

-1.0%

MCRB RSI Chart

MCRB Valuation

Market Cap

157.0M

Price/Earnings (Trailing)

29.12

Price/Sales (Trailing)

0.9

Price/Free Cashflow

-6.72

MCRB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MCRB Fundamentals

MCRB Revenue

Revenue (TTM)

127.8M

Rev. Growth (Yr)

189.13%

Rev. Growth (Qtr)

19.55%

MCRB Earnings

Earnings (TTM)

5.4M

Earnings Growth (Yr)

-90.76%

Earnings Growth (Qtr)

141.32%

MCRB Profitability

Return on Equity

12.34%

Return on Assets

3.76%

Free Cashflow Yield

-14.88%

MCRB Investor Care

Shares Dilution (1Y)

5.97%

Diluted EPS (TTM)

0.44

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	0	0	0
2023	0	132.1M	131.2M	127.8M
2022	110.5M	76.0M	41.6M	7.1M
2021	26.1M	30.0M	155.3M	144.9M
2020	35.4M	28.9M	23.3M	33.2M
2019	31.6M	39.5M	37.5M	34.5M
2018	33.1M	34.7M	20.7M	28.3M
2017	22.1M	22.1M	32.1M	32.1M
2016	5.9M	11.2M	16.5M	21.8M
2015	0	0	0	638.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Seres Therapeutics Inc

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with SociÃƒÆ’Ã‚Â©tÃƒÆ’Ã‚Â© des Produits NestlÃƒÆ’Ã‚Â© S.A. (NestlÃƒÆ’Ã‚Â©) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Eric D. Shaff M.B.A.
WEBSITE	serestherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	431

Seres Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Seres Therapeutics Inc? What does MCRB stand for in stocks?

MCRB is the stock ticker symbol of Seres Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seres Therapeutics Inc (MCRB)?

As of Wed Dec 03 2025, market cap of Seres Therapeutics Inc is 157.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MCRB stock?

You can check MCRB's fair value in chart for subscribers.

Is Seres Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MCRB is over valued or under valued. Whether Seres Therapeutics Inc is cheap or expensive depends on the assumptions which impact Seres Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MCRB.

What is Seres Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, MCRB's PE ratio (Price to Earnings) is 29.12 and Price to Sales (PS) ratio is 0.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MCRB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Seres Therapeutics Inc's stock?

In the past 10 years, Seres Therapeutics Inc has provided -0.31 (multiply by 100 for percentage) rate of return.